Clinical trials: Hodgkins Lymphoma
Refractory or Relapsed B-cell Non-Hodgkin Lymphoma
A Study Evaluating Safety and Efficacy of C-CAR011 in Subjects With B-NHL
This is a single arm, single-center, non-randomized study to evaluate the safety and efficacy of C-CAR011 in relapsed or refractory B cell Non-Hodgkin Lymphoma (NHL).
- Trial name
- NCT03299738
- Testing
- C-CAR011
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shanghai AbelZeta Ltd.
T-cell Lymphoma
A Phase II Clinical Trial of Lenalidomide for T-cell Non-Hodgkin's Lymphoma
T-cell Non-Hodgkin's lymphomas are a group of cancers that are usually treated with chemotherapy, radiation therapy, or occasionally surgery. T-cell lymphomas are relatively uncommon and therefore not well studied.
- Trial name
- NCT00322985
- Testing
- Lenalidomide
- Where
- 5 sites in Canada
- Volunteers
- 40 people
- Sponsor
- AHS Cancer Control Alberta
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
This phase II Pediatric MATCH trial studies how well vemurafenib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with BRAF V600 mutations that have spread to other places in the body…
- Conditions
- Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma, Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma, Ependymoma
- Trial name
- NCT03220035
- Testing
- Laboratory Biomarker Analysis, Vemurafenib
- Where
- 116 sites in United States, Puerto Rico
- Volunteers
- 4 people
- Sponsor
- National Cancer Institute (NCI)
Hodgkin Lymphoma, Lymphocytic Leukemia
Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies
Background: Allogeneic blood and marrow stem cell transplantation (BMT) plays an important role in the curative treatment of a number of pediatric malignancies.
- Conditions
- Hodgkin Lymphoma, Lymphocytic Leukemia, Mixed Cell Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT00013533
- Testing
- Stem cell transplantation
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Myeloproliferative Disorders, Leukemia
12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00004058
- Testing
- tetradecanoylphorbol acetate
- Where
- United States
- Sponsor
- University of Medicine and Dentistry of New Jersey
Recurrent Adult Hodgkin Lymphoma
Temsirolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
This phase I trial studies the side effects and best dose of temsirolimus when given together with brentuximab vedotin in treating patients with Hodgkin lymphoma that has returned or has not responded to treatment.
- Trial name
- NCT01902160
- Testing
- Brentuximab Vedotin, Laboratory Biomarker Analysis, Temsirolimus
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma
Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell Malignances
This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of non-gene edited anti-CD7 CAR (also called anti-CD7 CAR) T cells in patients with relapsed and/or refractory T…
- Conditions
- T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma, T-cell Non-Hodgkin Lymphoma
- Trial name
- NCT04934774
- Testing
- CD7 CAR T cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- iCell Gene Therapeutics
Lymphoma, Non-Hodgkin, Lymphoma, Follicular
Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell Lymphomas
This research study will only include two types of non-Hodgkin Lymphoma (NHL), follicular lymphoma or marginal zone lymphoma and participants will be age 70 or older.
- Conditions
- Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Low-Grade
- Trial name
- NCT01263418
- Testing
- Ofatumumab
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Relapsed Non-Hodgkin's Lymphoma, Hodgkin's Disease
Host Dendritic Cells in Allograft Patients
The purpose of this study is to assess preliminary efficacy and to determine the safety and feasibility of ex vivo generated dendritic cell (HDC) infusion with and without donor lymphocyte infusion (DLI) after allogeneic stem…
- Conditions
- Relapsed Non-Hodgkin's Lymphoma, Hodgkin's Disease, Multiple Myeloma, Chronic Lymphocytic Lymphoma
- Trial name
- NCT00935597
- Testing
- MSSM/BIIR HDC Vax-001 (Host Dendritic Cells)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Lymphoma, Non-Hodgkin, Hodgkin Disease
Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients
The purpose of this study is to determine the safety and effectiveness of TXA127 in accelerating the time it takes for patients to recover their platelet counts following a Autologous Peripheral Blood Stem Cell transplant.
- Conditions
- Lymphoma, Non-Hodgkin, Hodgkin Disease, Multiple Myeloma
- Trial name
- TXA127-PBSC (NCT01121120)
- Testing
- TXA127
- Where
- 10 sites in United States
- Volunteers
- 75 people
- Sponsor
- Tarix Pharmaceuticals
Neutropenic Enterocolitis, Myeloablative Chemotherapy Induced Bone Marrow Aplasia
Effectiveness and Safety of MMSCs for Enhancing Hematopoietic Recovery and Prophylaxis of Neutropenic Enterocolitis
Subjects will undergo peripheral blood stem cell mobilisation and collection with subsequent high-dose chemotherapy. After finalization of high-dose chemotherapy subjects will receive bone marrow derived allogeneic multipotent…
- Trial name
- NCT02145923
- Testing
- Peripheral blood stem cell mobilisation and collection, High-dose chemotherapy, Bone marrow derived allogeneic MMSCs infusion
- Where
- Russia
- Volunteers
- 16 people
- Sponsor
- Burnasyan Federal Medical Biophysical Center
Non-Hodgkin Lymphoma Refractory/ Relapsed, DLBCL - Diffuse Large B Cell Lymphoma
This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
This study is a first-in-human (FIH), Phase 1, multicenter, open-label study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and evaluate the preliminary anti-tumor activity of LTZ-301 administered as a…
- Conditions
- Non-Hodgkin Lymphoma Refractory/ Relapsed, DLBCL - Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma (MCL), Follicular Lymphoma ( FL)
- Trial name
- NCT07121946
- Testing
- LTZ-301
- Where
- 6 sites in United States
- Volunteers
- 42 people
- Sponsor
- LTZ Therapeutics, Inc.
Lymphoma
SWOG-8947 Collecting and Storing Blood Samples From Patients With Previously Untreated Non-Hodgkin Lymphoma
RATIONALE: Collecting and storing samples of blood from patients with cancer to test in the laboratory may help the study of cancer in the future.
- Trial name
- NCT01000558
- Testing
- biologic sample preservation procedure
- Where
- 203 sites in United States
- Volunteers
- 939 people
- Sponsor
- SWOG Cancer Research Network
Lymphoma
A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)
The purpose of this study is to assess the safety and efficacy of parsaclisib in subjects with relapsed or refractory diffuse large B-cell lymphoma.
- Trial name
- NCT02998476
- Testing
- Parsaclisib
- Where
- 70 sites in United States, Australia and 9 more
- Volunteers
- 60 people
- Sponsor
- Incyte Corporation
Non-Hodgkin's Lymphoma
Zevalin-beam for Aggressive Lymphoma
The study hypothesis is that the addition of zevalin radioimmunotherapy to the conditioning regimen given prior to BEAM high-dose chemotherapy and autologous stem cell transplantation in patients with aggressive lymphoma will…
- Trial name
- NCT00491491
- Testing
- ibritumomab tiuxetan, BEAM chemotherapy and autologous stem-cell transplantation
- Where
- 9 sites in United States, Germany and 2 more
- Volunteers
- 60 people
- Sponsor
- Sheba Medical Center
Anemia, Leukemia
Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer
RATIONALE: Darbepoetin alfa and epoetin alfa may stimulate red blood cell production and treat anemia in patients who are receiving chemotherapy.
- Conditions
- Anemia, Leukemia, Lymphoma, Lymphoproliferative Disorder
- Trial name
- NCT00070382
- Testing
- darbepoetin alfa, epoetin alfa
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Non-Hodgkin's Lymphoma
Phase I/II Trial of VELCADE + CHOP-Rituximab in Untreated DLCBL or Mantle Cell NHL
Primary Objective: To determine the toxicity profile and maximum tolerated dose (MTD) of VELCADE when administered in combination with CHOP + Rituximab to patients with previously untreated diffuse large B cell or mantle cell…
- Trial name
- NCT00151320
- Testing
- Bortezomib, CHOP, Rituximab
- Where
- 4 sites in United States
- Volunteers
- 76 people
- Sponsor
- Weill Medical College of Cornell University
Non-Hodgkin Lymphoma
A Safety Study of SGN-40 in Patients With Non-Hodgkin's Lymphoma
This is an open-label, multi-dose, Phase I, dose escalation study to define the safety profile and preliminary anti-tumor activity of SGN-40 in patients with refractory or recurrent non-Hodgkin B-cell lymphomas.
- Trial name
- NCT00103779
- Testing
- SGN-40 (anti-huCD40 mAb)
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- Seagen Inc.
Lymphoma, Non-Hodgkin
Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab) for Previously Untreated, Advanced-stage, Low Grade Non-Hodgkin's Lymphoma
This is a single-arm, single-institution, phase II study of Iodine-131 Anti-B1 Antibody for patients with previously untreated, advanced-stage (stage III or IV) low-grade non-Hodgkin's B-cell lymphoma.
- Trial name
- NCT00996996
- Testing
- Tositumomab and Iodine I 131 Tositumomab (Anti-B1 Antibody and Iodine-131 Anti-B1 Antibody)
- Volunteers
- 77 people
- Sponsor
- GlaxoSmithKline
Myeloproliferative Disorders, Leukemia
Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy before a donor umbilical cord blood transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00827099
- Testing
- anti-thymocyte globulin, fludarabine phosphate, Melphalan
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Northside Hospital, Inc.